Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jill Fulcher"'
Autor:
Anne Tierens, Tracy L. Stockley, Clinton Campbell, Jill Fulcher, Brian Leber, Elizabeth McCready, Peter J. B. Sabatini, Bekim Sadikovic, Andre C. Schuh
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1376-1387 (2021)
Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of M
Externí odkaz:
https://doaj.org/article/8f0d09c1a92f4093bb4e91866492160c
Publikováno v:
Annals of Hematology. 101:1137-1139
Autor:
Jill Fulcher, Janine Malcolm, Erin Keely, Sanjay Murthy, Jeffrey McCurdy, Melanie Chin, Shawn D. Aaron, Ena Gaudet, Antonio Cabral, Eilish McConville, Johnathan Mack, Melissa Toupin, Timothy Ramsay, Christopher Bredeson, Philip Wells
Background: Transfer of young adults (YAs) with chronic diseases from pediatric- to adult hospital-based care is a major life event for this vulnerable group of patients. Inadequate preparation of the YAs and poorly planned transition of care are ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d7739b73c466b73b4bb3b22895533d0
https://doi.org/10.21203/rs.3.rs-1443555/v1
https://doi.org/10.21203/rs.3.rs-1443555/v1
Publikováno v:
Transplantation and Cellular Therapy. 29:131.e1-131.e6
Increasing use of hematopoietic stem cell transplantation (HCT) and improvements in recipient outcomes have led to a steady increase in the number of allogeneic HCT survivors. In addition to complications specific to the transplantation process, HCT
Autor:
Eberhard L. Renner, David M. Grant, Harold Atkins, Natasha Kekre, Mark S. Cattral, Andrzej Chruscinski, Andrea Kew, Anne Marie Clement, Mitchell Sabloff, Kathryn Tinckham, David S. Allan, Robert B. Smith, Christopher Bredeson, Oyedele Adeyi, Anthony J. Demetris, Tae Kyoung Kim, Jianhua Zhang, Leslie B. Lilly, Atul Humar, Meaghan Macarthur, Sultan Altouri, S. Moshkelgosha, Isabelle Bence-Bruckler, Paul D. Greig, Stephen C. Juvet, Nazia Selzner, Tae Joon Yi, Anand Ghanekar, Korosh Khalili, Ian D. McGilvray, Gonzalo Sapisochin, Lisa Martin, Zita Galvin, Maor Epstein, Lothar Huebsch, Sandra Fischer, Jill Fulcher, Sheryl McDiarmid, Markus Selzner, Gary A. Levy
Publikováno v:
Transplantation. 106(3)
Background Primary sclerosing cholangitis (PSC) is an indication for liver transplantation, but recurrence after liver transplantation is associated with poor outcomes often requiring repeat transplantation. We investigated whether autologous hematop
Autor:
Jill Fulcher, Pierre J A Villeneuve, Mitchell Sabloff, Philip Berardi, Christopher Bredeson, Grace Christou
Publikováno v:
Leukemialymphoma. 62(9)
T-Acute lymphoblast leukemia (T-ALL) accounts for 25-30% of adult ALL and occurs more frequently in young adults. Up to 35% of adults with T-ALL have a high-risk subtype called Early T-cell precurs...
Autor:
Tim Ramsay, Harold L. Atkins, Christopher Bredeson, Sultan Altouri, Rajiv Samant, David S. Allan, Lothar Huebsch, Natasha Kekre, Dawn Maze, Jill Fulcher, Mitchell Sabloff
Publikováno v:
Bone Marrow Transplantation. 55:1454-1456
Autor:
Tracy Stockley, Andre C. Schuh, Peter J. B. Sabatini, Anne Tierens, Bekim Sadikovic, Jill Fulcher, Brian Leber, Clinton J. V. Campbell, Elizabeth McCready
Publikováno v:
Paediatrics Publications
Current Oncology, Vol 28, Iss 131, Pp 1376-1387 (2021)
Current Oncology
Volume 28
Issue 2
Pages 131-1387
Current Oncology, Vol 28, Iss 131, Pp 1376-1387 (2021)
Current Oncology
Volume 28
Issue 2
Pages 131-1387
Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9832502055b5376b405ed8306655a7fd
https://ir.lib.uwo.ca/paedpub/1735
https://ir.lib.uwo.ca/paedpub/1735
Publikováno v:
Leukemialymphoma. 61(9)
Despite an initial 80–90% response rate to therapy, approximately 50% of adult patients with B-acute lymphoblastic leukemia (B-ALL) subsequently relapse. Historically allogeneic hematopoietic stem ...
Publikováno v:
CMAJ : Canadian Medical Association Journal
Trois ans apres la greffe de cellules souches (GCS) hematopoietiques, la probabilite de survie est de 30 % a 60 %, et les cas de recurrence de la maladie comptent pour 50 %–60 % des deces[1][1]. La maladie cardiovasculaire, la malignite secondaire